K.R. Islamov1, L.G. Karpenko1, B.I. Gataullin1-3, R.G. Islamov2, I.G. Gataullin1
1Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
2Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan
3Kazan (Volga Region) Federal University, Kazan
Islamov Karim R. ― 2-year resident of the Department of Oncology, Radiology and Palliative Medicine of the Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia
36 Butlerov Str., Kazan, 420012, Russian Federation, ORCID ID: 0000-0002-8699-715X
Abstract. In Russia, kidney cancer is in 7th place in terms of prevalence, and in the structure of malignant neoplasms it is 4,9%. Lack of biomarkers to assess disease prognosis may result in a poor clinical response. Therefore, it is necessary to search for prognostic biomarkers to assess long-term results of kidney cancer treatment. A number of studies have shown that the etiology of renal cell carcinoma is related to the hormonal status of patients. In particular, it has been found that estrogens and their receptors play a crucial role in the occurrence of various types of cancer, including kidney cancer, and high expression of estrogen receptors can serve as an unfavorable prognostic indicator of renal cell carcinoma. The paper analyzes the literature sources on the influence of the status of estrogen receptors of a kidney tumor on the prognosis of the disease.
Key words: renal cell carcinoma, estrogen receptors, prognosis.